Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

Drugs of Today

Volumn 41, Issue 12, 2005, Pages 773-784

  Strumberg, Dirk ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; DACARBAZINE; DOXORUBICIN; FLT3 LIGAND; GEFITINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD DISEASE; BONE MARROW DISEASE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; FATIGUE; FLUSHING; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; LETHARGY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SARCOMA; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA;

EID: 33644684217     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.12.937959     Document Type: Review

References (78)

1. Zwick, E., Bange, J., Ullrich, A. Receptor tyro-sine kinases as targets for anticancer drugs. Trends Mol Med 2002, 8: 17-23.
2. Herrera, R., Sebolt-Leopold, J.S. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002, 8(Suppl. 4): S27-31.
3. Marshall, C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994, 4: 82-9.
4. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103: 211-25.
5. Magne, N., Fischel, J.L., Dubreuil, A. et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002, 86: 1518-23.
6. Barnes, C.J., Bagheri-Yarmand, R., Mandal, M. et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003, 2: 345-51.
7. Lokker, N.A., Sullivan, C.M., Hollenbach, S.J., Israel, M.A., Giese, N.A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002, 62: 3729-35.
8. Doanes, A.M., Hegland, D.D., Sethi, R., Kovesdi, I., Bruder, J.T., Finkel, T. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem Biophys Res Commun 1999, 255: 545-8.
9. Meadows, K.N., Bryant, P., Pumiglia, K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001, 276: 49289-98.
10. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol 1999, 71: 479-500.
11. Kolch, W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351 (Pt. 2): 289-305.
12. Lewis, T.S., Shapiro, P.S., Ahn, N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74: 49-139.
13. Robinson, M.J., Cobb, M.H. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997, 9: 180-6.
14. Dhanasekaran, N., Premkumar Reddy, E. Signaling by dual specificity kinases. Oncogene 1998, 17 (11 Reviews): 1447-55.
15. Harrisingh, M.C., Lloyd, A.C. Ras/Raf/ERK signalling and NF1. Cell Cycle 2004, 3: 1255-8.
16. O'Neill, E., Kolch, W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004, 90: 283-8.
17. Chong, H., Vikis, H.G., Guan, K.L. Mechanisms of regulating the Raf kinase family. Cell Signal 2003, 15: 463-9.
18. Mercer, K.E., Pritchard, C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653: 25-40.
19. Morrison, D.K., Cutler, R.E. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997, 9: 174-9.
20. Hagemann, C., Rapp, U.R. Isotype-specific functions of Raf kinases. Exp Cell Res 1999, 253: 34-46.
21. Katz, M.E., McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997, 7: 75-9.
22. Chang, F., Steelman, L.S., Lee, J.T. et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003, 17: 1263-93.
23. Davis, R.J. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995, 42: 459-67.
24. Coffer, P., de Jonge, M., Mettouchi, A., Binetruy, B., Ghysdael, J., Kruijer, W. junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2. Oncogene 1994, 9: 911-21.
25. Dalby, K.N., Morrice, N., Caudwell, F.B., Avruch, J., Cohen, P. Identification of regulatory phos-phorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J Biol Chem 1998, 273: 1496-505.
26. Fukunaga, R., Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 1997, 16: 1921-33.
27. Waskiewicz, A.J., Flynn, A., Proud, C.G., Cooper, J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997, 16: 1909-20.
28. Suzuki, T., K-Tsuzuku, J., Ajima, R., Nakamura, T., Yoshida, Y., Yamamoto, T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 2002, 16: 1356-70.
29. Schulze, A., Lehmann, K., Jefferies, H.B., McMahon, M., Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001, 15: 981-94.
30. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949-54.
31. Kimura, E.T., Nikiforova, M.N., Zhu, Z., Knauf, J.A., Nikiforov, Y.E., Fagin, J.A. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63: 1454-7.
32. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. High frequency of BRAF mutations in nevi. Nat Genet 2003, 33: 19-20.
33. Dong, J., Phelps, R.G., Qiao, R. et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003, 63: 3883-5.
34. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., Tuveson, D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63: 5198-202.
35. Eisenmann, K.M., VanBrocklin, M.W., Staffend, N.A., Kitchen, S.M., Koo, H.M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003, 63: 8330-7.
36. Alavi, A., Hood, J.D., Frausto, R., Stupack, D.G., Cheresh, D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301: 94-6.
37. Hood, J.D., Bednarski, M., Frausto, R. et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296: 2404-7.
38. Wojnowski, L., Zimmer, A.M., Beck, T.W. et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997, 16: 293-7.
39. Huser, M., Luckett, J., Chiloeches, A. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001, 20: 1940-51.
40. Reinmuth, N., Parikh, A.A., Ahmad, S.A. et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003, 60: 199-207.
41. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285: 1182-6.
42. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986, 46: 467-73.
43. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82: 4-6.
44. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
45. Korc, M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003, 2: 8.
46. Tischer, E., Mitchell, R., Hartman, T. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266: 11947-54.
47. Auguste, P., Javerzat, S., Bikfalvi, A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 2003, 314: 157-66.
48. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111: 1287-95.
49. Yang, J.C., Haworth, L., Sherry, R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427-34.
50. Adams, J., Huang, P., Patrick, D. A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol 2002, 6: 486-92.
51. Laird, A.D., Cherrington, J.M. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin Investig Drugs 2003, 12: 51-64.
52. Wilhelm, S., Chien, D.S. BAY 43-9006: Preclinical data. Curr Pharm Des 2002, 8: 2255-7.
53. Shih, C., Teicher, B.A. Cryptophycins: A novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des 2001, 7: 1259-76.
54. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64: 7099-109.
55. Harwerth, I.M., Wels, W., Schlegel, J., Muller, M., Hynes, N.E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993, 68: 1140-5.
56. Hsieh, S.S., Malerczyk, C., Aigner, A., Czubayko, F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer 2000, 86: 644-51.
57. Strumberg, D., Bauer, R.J., Moeller, J.G. et al. Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Proc Am Soc Clin Oncol, Orlando 2002, 21: Abst. 121.
58. Strumberg, D., Voliotis, D., Moeller, J.G. et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002, 40: 580-1.
59. Strumberg, D., Richly, H., Hilger, R.A. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-72.
60. Richly, H., Kupsch, P., Passage, K. et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004, 42: 650-1.
61. Kupsch, P., Passage, K., Richly, H. et al. Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors. ASCO 40th Annual Meeting Proceedings, New Orleans 2004, 22: 209s, Abst. 3056.
62. Steinbild, S., Baas, F., Gmehling, D., Brendel, E., Christensen, O., Schwartz, B.K.M. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. ASCO 41st Annual Meeting Proceedings, Orlando 2005, 43: 220s, Abst. 3115.
63. Siu, L., Takimoto, C., Awada, A. et al. A phase I/II trial of BAY 43-9006 and gemcitabine in advanced pancreatic cancer. ASCO 40th Annual Meeting Proceedings, New Orleans 2004, 22: 209s, Abst. 3059.
64. Flaherty, K., Brose, M., Schuchter, L. et al. Phase I/II trial of BAY 43-9006, carboplatin (C), and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. ASCO 40th Annual Meeting Proceedings, New Orleans 2004, 22: 711s, AbSt. 7507.
65. Adjei, A.A., Mandrekar, S., Marks, R.S. et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). ASCO 41st Annual Meeting Proceedings, Orlando 2005, 43: 208s, Abst. 3067.
66. Karasarides, M., Chiloeches, A., Hayward, R. et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23: 6292-8.
67. Ahmad, T., Marais, R., Pyle, L. et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. ASCO 40th Annual Meeting Proceedings, New Orleans 2004, 22: 711s, Abst. 7506.
68. Flaherty, K.T., Redlinger, M., Schuchter, L.M., Lathia, C.D., Weber, B.L., P.J. OD: Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. ASCO 41st Annual Meeting Proceedings, Orlando 2005, 43: 201s, Abst. 3037.
69. Flaherty, K.T. New molecular targets in melanoma. Curr Opin Oncol 2004, 16: 150-4.
70. Zimpfer-Rechner, C., Hofmann, U., Figl, R. et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003, 13: 531-6.
71. Hodi, F.S., Soiffer, R.J., Clark, J., Finkelstein, D.M., Haluska, F.G. Phase Il study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002, 25: 283-6.
72. Eisen, T., Ahmad, T., Gore, M.E. et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. ASCO 41st Annual Meeting Proceedings, Orlando 2005, 43: 712s, Abst. 7508.
73. Abou-Alfa, G.K., Schwartz, L., Ricci, S. et al. Phase II study of Bay 43-9006 in patients with advanced hepatocellular carcinoma (HCC). AACR-NCI-WORTC International Conference on Molecular Targets and Cancer Therapeutics, Geneva 2004.
74. Siu, L.L., Winquist, E., Agulnik, M. et al. A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). ASCO Proceedings, Orlando 2005, 23: 516s, Abst. 5556.
75. Ratain, M.J., Eisen, T., Stadler, W.M. et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO 41st Annual Meeting Proceedings, Orlando 2005, 21: 388s, Abst. 4544.
76. O'Dwyer, P.J., Rosen, M., Gallagher, M., Schwartz, B., Flaherty, K.T. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. ASCO 41st Annual Meeting Proceedings, Orlando 2005, 23: 193s, Abst. 3005.
77. Pacey, S., Ratain, M.J., O'Dwyer, P.J. et al. Preliminary assessment of BAY 43-9006 in advanced sarcoma patients using the randomized discontinuation design. AACR-NCI-WORTC International Conference on Molecular Targets and Cancer Therapeutics, Geneva 2004.
78. Escudier, B., Szczylik, C., Eisen, T. et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO 41st Annual Meeting Proceedings, Orlando 2005, 43: 380s, Abst. 4510.